Back
  1. Home
  2. Profile of Karolina PAVIC (Unilu)
Profil

PAVIC Karolina

University of Luxembourg > Faculty of Science, Technology and Medicine (FSTM) > Department of Life Sciences and Medicine (DLSM)

Main Referenced Co-authors
ABANKWA, Daniel  (5)
MANOHARAN, Ganesh Babu  (3)
GAIGNEAUX, Anthoula  (2)
Grossmann, Tom N. (2)
Knuuttila, Matias (2)
Main Referenced Keywords
Ras (2); Amino Acids (1); Carcinogenesis/genetics/metabolism (1); Catalytic Domain (1); Drug development (1);
Main Referenced Disciplines
Biochemistry, biophysics & molecular biology (5)

Publications (total 5)

The most downloaded
52 downloads
Pavic, K., Gupta, N., Omella, J. D., Derua, R., Aakula, A., Huhtaniemi, R., Määttä, J. A., Höfflin, N., Okkeri, J., Wang, Z., Kauko, O., Varjus, R., Honkanen, H., Abankwa, D., Köhn, M., Hytönen, V. P., Xu, W., Nilsson, J., Page, R., ... Westermarck, J. (2023). Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A. Nature Communications, 14 (1), 1143. doi:10.1038/s41467-023-36693-9 https://hdl.handle.net/10993/55545

The most cited

11 citations (WOS)

Pavic, K., Gupta, N., Omella, J. D., Derua, R., Aakula, A., Huhtaniemi, R., Määttä, J. A., Höfflin, N., Okkeri, J., Wang, Z., Kauko, O., Varjus, R., Honkanen, H., Abankwa, D., Köhn, M., Hytönen, V. P., Xu, W., Nilsson, J., Page, R., ... Westermarck, J. (2023). Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A. Nature Communications, 14 (1), 1143. doi:10.1038/s41467-023-36693-9 https://hdl.handle.net/10993/55545

MANOHARAN, G. B., STEFFEN, C., PAVIC, K., Yeste-Vázquez, A., Knuuttila, M., Arora, N., Zhou, Y., Härmä, H., GAIGNEAUX, A., Grossmann, T. N., & ABANKWA, D. (2023). Identification of an H-Ras nanocluster disrupting peptide. Cold Spring Harbor Laboratory. doi:10.1101/2023.09.07.556635

KAYA, P., SCHAFFNER-RECKINGER, E., MANOHARAN, G. B., Vukic, V., Kiriazis, A., LEDDA, M., Burgos, M., PAVIC, K., GAIGNEAUX, A., GLAAB, E., & ABANKWA, D. (2023). An improved PDE6D inhibitor combines with Sildenafil to synergistically inhibit KRAS mutant cancer cell growth. ORBilu-University of Luxembourg. https://orbilu.uni.lu/handle/10993/58308. doi:10.1101/2023.08.23.554263

Pavic, K., Gupta, N., Omella, J. D., Derua, R., Aakula, A., Huhtaniemi, R., Määttä, J. A., Höfflin, N., Okkeri, J., Wang, Z., Kauko, O., Varjus, R., Honkanen, H., Abankwa, D., Köhn, M., Hytönen, V. P., Xu, W., Nilsson, J., Page, R., ... Westermarck, J. (2023). Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A. Nature Communications, 14 (1), 1143. doi:10.1038/s41467-023-36693-9
Peer Reviewed verified by ORBi

MANOHARAN, G. B., PAVIC, K., Yeste Vazquez, A., Knuuttila, M., Grossmann, T. N., ABANKWA, D., & STEFFEN, C. (13 September 2022). Identification of a small peptide targeting the Raf/ Galectin interface to disrupt stabilised Ras signalling nanocluster [Paper presentation]. Small G proteins in cellular signalling and disease, Liverpool, United Kingdom.

Pavic, K., Chippalkatti, R., & Abankwa, D. (2022). Drug targeting opportunities en route to Ras nanoclusters. Advances in Cancer Research, 153, 63-99. doi:10.1016/bs.acr.2021.07.005
Peer Reviewed verified by ORBi

Contact ORBilu